Clinical efficacy and safety of secukinumab in patients with psoriasis and comorbidities: pooled analysis of 4 phase 3 clinical trials

The influence of comorbidities on the efficacy and safety of biologic therapies in psoriasis has not been rigorously explored. To assess the incremental burden of comorbidities on clinical efficacy and safety of secukinumab vs. etanercept and placebo among patients with plaque psoriasis pooled from...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of dermatological treatment 2022-04, Vol.33 (3), p.1482-1490
Main Authors: Gottlieb, Alice B., Wu, Jashin J., Griffiths, Christopher E. M., Marfo, Kwaku, Muscianisi, Elisa, Meng, Xiangyi, Frueh, Jennifer, Lebwohl, Mark
Format: Article
Language:English
Subjects:
comorbidities
Plaque psoriasis
secukinumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The influence of comorbidities on the efficacy and safety of biologic therapies in psoriasis has not been rigorously explored. To assess the incremental burden of comorbidities on clinical efficacy and safety of secukinumab vs. etanercept and placebo among patients with plaque psoriasis pooled from 4 phase 3 trials. Efficacy was assessed at week 12 according to achievement of Psoriasis Area and Severity Index (PASI) and Investigator's Global Assessment (IGA; modified 2011) responses. Efficacy comparisons between treatment arms stratified by comorbidity status were made using logistic regression analysis with nonresponder imputation. Relationships between baseline characteristics and clinical responses were evaluated by χ 2 tests. Of 2401 patients, 1469 (61.2%) had ≥1 active baseline comorbidity. Regardless of comorbidity status, patients receiving secukinumab were more likely to achieve PASI and IGA responses than those receiving etanercept or placebo at week 12 (p 
ISSN:0954-6634
1471-1753
DOI:10.1080/09546634.2020.1832187